Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in Pancreatic Cancer

Novel, tumor-selective therapies are needed to increase the survival rate of pancreatic cancer patients. K-Ras-mutant-driven NAD(P)H:quinone oxidoreductase 1 (NQO1) is over-expressed in pancreatic tumor vs associated normal tissue, while catalase expression is lowered compared to levels in associate...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Surg Oncol
Main Authors: Beg, Muhammad Shaalan, Huang, Xiumei, Silvers, Molly A., Gerber, David E., Bolluyt, Joyce, Sarode, Venetia, Fattah, Farjana, Deberardinis, Ralph J., Merritt, Matthew E., Xie, Xian-Jin, Leff, Richard, Laheru, Daniel, Boothman, David A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5509448/
https://ncbi.nlm.nih.gov/pubmed/28346693
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jso.24624
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados